Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now

You can switch off notifications anytime using browser settings.
Stock Analysis, IPO, Mutual Funds, Bonds & More

Retail investors may skip Aditya Birla SL Mutual Fund's pharma NFO

In addition to drug makers, the scheme will also invest in allied segments

, ET Bureau|
Jun 26, 2019, 09.33 AM IST
Getty Images
Investors could stay away from the new fund offer (NFO) of Aditya Birla Sun Life Pharma and Healthcare Fund, said investment advisors. This is the fifth new fund offer in the pharma and healthcare space in the last one year.

This NFO comes when pharma sector returns have disappointed investors. MFs including ICICI Prudential, Mirae Asset, DSP and IDBI have launched their NFOs in the last one year and there are now nine schemes investing in the pharma sector. Returns from the sector have been subdued in the last three years as drug makers grapple with compliance issues and pricing pressures.

As per data from Value Research, the pharma sector has lost 5.15% in the last one year and 2.38% over the last three years.

Aditya Birla Sun Life Pharma and Healthcare Fund, which will be managed by Dhaval Shah will close for subscription on July 5. The scheme will invest in allied segments like hospitals and diagnostics, wellness businesses or the global contract research and manufacturing services industry in addition to drug makers. The fund will pick up international pharma companies which have businesses that are not available in India.

The fund manager is betting on a revival in exports. With valuations 20% below long-term averages, the fund is looking for value picks. Financial planners said investors should stay away from sectoral funds and NFOs which do not have a track record.

“Sector funds take concentrated bets and are meant for informed investors. Retail investors could stay away and build their portfolios through diversified equity MFs,” says Vijay Kuppa, founder, Orowealth.

Also Read

NFO Review: DSP Quant Fund

NFO review: Mirae Asset Midcap Fund

Risk-taking mutual fund investors can invest in Mirae NFO

‘NFO of Parag Parikh Tax Saver Fund can be avoided’

‘Retail investors may skip AB Sun Life’s Pharma NFO’

Add Your Comments
Commenting feature is disabled in your country/region.
Download The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.

Other useful Links

Follow us on

Download et app

Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service